Blog

Verily, the precision health company from Alphabet (Google's parent company), has launched Verily Me, a free consumer health app designed to act as a personal health record and more.Key features and details include:Personal Health Record Aggregation: The app securely retrieves and consolidates a user's medical records (including medications, conditions, procedures, immunisations,and test results) from multiple providers and health information exchanges (HIEs) into one cohesive, longitudinal view. It can often integrate data from wearables via Apple HealthKit and Google Health Connect. Personalised Health Recommendations: Licensed clinicians review the aggregated medical records to provide personalized and preventative health recommendations, helping users identify care gaps.AI Companion (Violet): The app includes an AI assistant named Violet that can answer personal and private questions about the user's health record, such as "When was my last flu vaccination?" or "Explain my cholesterol trends."Meal Logging: Users can snap a photo of their meal for real-time feedback and nutrition tips. Research Participation: Users have the option to consent to participate in Verily's Lifelong Health Study, a real-world research registry.Availability: Verily Me is a free app available to the general public (currently in the US) and can be downloaded from the Apple App Store and Google Play.Verily MeVerily Me is a very recent product launch, but its history is rooted in Verily's broader shift toward AI-driven data platforms and consumer-facing health solutions.Here is a brief history:Predecessor Context (Verily's Evolution): Verily, formerly Google Life Sciences, was founded in 2015 as a moonshot from Google's "X" division. While its early projects focused on hardware and large-scale studies (like Project Baseline launched in 2017), the company has recently pivoted to prioritize software, AI, and data infrastructure. Existing Care Program: Verily had been providing virtual care solutions to patients since 2018. This experience, particularly with its Lightpath chronic care management program, laid the groundwork for integrating clinical services with its technology. Platform Foundation: The Verily Me app was built using Verily's precision health platform, Pre. This platform is designed to transform complex, multimodal datasets for use across AI-enabled healthcare, and it forms the technical backbone for Verily's new solutions. Official Launch: October 2025: Verily Me was officially unveiled and launched as a free consumer health app on October 17, 2025, at the HLTH USA conference. Purpose: The launch of Verily Me represents Verily's most direct move into the consumer health market, aiming to address the problem of fragmented medical records and provide personalised, proactive health guidance by combining:Medical record aggregation Review and recommendations from licensed clinicians An AI companion (Violet) to answer personal health record questions The Lifelong Health Study, a research registry that users can opt-in to, building upon the earlier Project Baseline foundation.Source: <a data-mce-href="https://www.verilyme.com/" href="https://www.verilyme.com/" title="https://www.verilyme.com/" target="_blank" rel="noopener">https://www.verilyme.com/</a>Download VerilyMe: <a data-mce-href="https://www.verilyme.com/download-app" href="https://www.verilyme.com/download-app" title="https://www.verilyme.com/download-app" target="_blank" rel="noopener">https://www.verilyme.com/download-app</a>

Google's parent company Alphabet launches Verily Me, a free Personal Health Record

Chess pieces overlaying financial data graphs with blue digital light effects on a blurred background.

The European HealthTech and MedTech market is experiencing distress, or a "market correction" after years of heavy Venture Capital (VC) investment due to a confluence of economic shifts and unique structural challenges specific to Europe's healthcare environment.The main reasons for this market distress are:1. Economic and Investor Sentiment Shifts The Funding Drought and Flight to Quality: After the "exuberance" and peak valuations of the COVID-19-driven VC boom (especially around 2021-2022), investors have become significantly more cautious and selective.High Interest Rates and Inflation have increased the cost of capital, making investors prioritise profitability over rapid, loss-making growth. VC investment has shifted to a "selective scale" model, concentrating capital in a few proven, high-conviction ventures (mega-deals) that have a clear path to profitability and strong clinical validation.This has left many startups that scaled quickly and raised at high valuations now facing a valuation mismatch, struggling to raise follow-on funding, resulting in "down rounds" (raising at a lower valuation) or forcing them into distressed mergers and acquisitions (M&amp;A).Correction in Digital Health: The adoption of many digital health solutions was "overestimated." Many B2C apps (like wellness platforms) have struggled to establish clear reimbursement pathways or sustainable revenue models, leading to a slowdown in their funding and making VCs shift focus towards more capital-intensive, hardware-backed, or AI-first segments like biotech and traditional medtech.2. Burdensome and Fragmented Regulatory Environment The transition to the EU Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR) is considered the most significant structural headwind, creating what the industry calls "structural problems."Complexity and Cost: The regulations are widely criticized as slow, unpredictable, costly, and excessively complicated. MedTech Europe reports that over 70% of manufacturers have needed to allocate substantial additional resources to meet compliance demands.Delays and Supply Risk: The new framework has caused severe delays in the certification and approval of medical devices, leading to concerns about bottlenecks, product shortages, and the withdrawal of existing, essential devices from the EU market, as many manufacturers struggle or decide not to recertify their entire portfolios.Hindered Innovation: The long and complex process has caused the manufacturer's choice of the EU as the first launch geography to drop significantly. Small and medium-sized enterprises (SMEs) report higher declines in new device development, as the lengthy gestation period and high costs make it difficult to support innovation.3. Market Fragmentation and Adoption Hurdles Siloed Healthcare Systems: Unlike the U.S. market, Europe's healthcare landscape is highly fragmented, consisting of numerous national health systems (like the NHS, German health funds, etc.) with their own budgets, priorities, and procurement processes.Difficult to Scale: Startups face a significant challenge in scaling a single solution across the entire EU due to linguistic, cultural, regulatory, and procurement differences between member states. This lack of a cohesive "single market" for healthcare makes it difficult to achieve the massive scale VCs demand.Slow Provider Adoption: Convincing healthcare providers and hospitals to adopt new technologies is slow, especially if the solutions require changing established clinical workflows or lack robust, long-term evidence of improved patient outcomes or cost savings.In short, the current distress is a combination of macroeconomic "sobering up" (investors demanding profit) and the high friction costs imposed by European regulatory hurdles (MDR/IVDR) and fragmented national markets.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Why is a lot of the European HealthTech market distressed following years of Venture Capital investment?

Teamwork and solution concept. 3D puzzle pieces

The European HealthTech M&amp;A and funding environment is characterised by a "flight to quality," increased investor selectivity, and a strong focus on proven business models and clear pathways to profitability. The market is maturing, favouring larger, strategic deals and companies with demonstrable clinical and financial success. Here are 10 key factors European HealthTech founders should be aware of: 1. Focus on Profitability and Recurring RevenueInvestors and acquirers have shifted from prioritising growth at all costs to demanding a clear path to profitability and strong unit economics. Valuation Premium: Companies with a high percentage of recurring revenue (e.g., Software-as-a-Service/subscription models) and high gross margins are receiving premium valuations (often 5.5x to 7x revenue multiples for value-based care/analytics solutions). Founder Focus: Clean up your financials and demonstrate a predictable, scalable revenue model that isn't dependent on one-off projects. &nbsp; 2. Definitive Clinical and Commercial Validation Unlike general tech, HealthTech's value is directly tied to real-world efficacy and measurable impact. Evidence is King: Buyers require robust, documented clinical studies and clear Return on Investment (ROI)for providers and payers. Due Diligence: Expect intense scrutiny on documented case studies that prove your product improves patient outcomes or generates cost savings. &nbsp; 3. Regulatory Compliance and Data Privacy (GDPR/EHDS) Regulatory risk is a major deal-breaker in due diligence, especially in Europe's complex, fragmented regulatory landscape. GDPR &amp; Security: Meticulous documentation and a flawless track record of adherence to GDPR (data privacy) and a formal Quality Management System (QMS) are non-negotiable. EHDS Impact: The impending European Health Data Space (EHDS) aims to create a single market for health data, offering immense opportunity but requiring strict adherence to new data sharing and interoperability standards. Compliance here is a new value driver. 4. Proprietary AI and Deep Technology "Moat" 🤖 AI/ML is the single biggest driver of valuation premiums, but only for proven, defensible technology. Premium Valuation: Companies with proprietary AI/ML algorithms that provide a clear competitive advantage (e.g., in diagnostics or predictive analytics) are seeing top-tier valuations (often 6x to 8x revenue multiples or more). Founder Focus: Clearly document and protect your unique technology Intellectual Property (IP) and be ready to demonstrate measurable outcomes and efficiency gains it provides. &nbsp; 5. Shift to Selective Scale and Late-Stage Investment The funding environment is heavily concentrated, with investors favouring larger, more mature companies. "Mega-Deals" Dominance: A few large late-stage deals ($100M+) are capturing a significant share of the total VC funding, indicating a "flight to quality". Early-Stage Caution: Early-stage companies face greater scrutiny, requiring stronger traction, a solid team, and clear evidence of product-market fit to secure initial funding. &nbsp; 6. Fragmented European Market and Cross-Border Scaling Scaling across Europe remains a core challenge due to national differences in healthcare systems. Market Fragmentation: Each member state has its own unique reimbursement, procurement, and adoption processes, making pan-European scaling costly and complex. Opportunity: Companies that successfully build solutions for interoperability, compliance SaaS, or systems integration that bridge this fragmentation are high-value M&amp;A targets. &nbsp; 7. Importance of a Strong, Scalable Management Team Acquirers are risk-averse regarding over-reliance on a single founder. Key Person Risk: Due diligence assesses if the company can operate and grow without the founder's daily involvement. A lack of a strong second-tier management team is a red flag. Founder Focus: Develop documented, repeatable processes (SOPs) and delegate key client relationships to demonstrate sustainability and scalability post-acquisition. 8. M&amp;A as the Primary Exit Path With the IPO market remaining largely stagnant, M&amp;A is the dominant route to liquidity. Acquirer Profile: Expect increased interest from large US and Asian strategic buyers seeking platform opportunities and access to the European market, alongside large European biopharma/MedTech players filling portfolio gaps. Alternative Structures: Be prepared for a rise in alternative deal structures like earn-outs and milestone-driven payments, which manage risk for acquirers in volatile markets. &nbsp; 9. Alignment with Value-Based Care and Cost Reduction The rising cost of healthcare puts pressure on providers to adopt solutions that deliver measurable savings. Investor Preference: Solutions that clearly enable the shift from a fee-for-service to a value-based care model are attracting high multiples. Founder Focus: Your pitch should centre on verifiable cost savings and clinical efficiency gains for healthcare systems, not just novel technology. 10. Geopolitical and Macroeconomic Headwinds Rising interest rates and global economic uncertainty continue to impact valuations and deal financing. Valuation Compression: While resilient, the average revenue multiple is down from its 2021 peak, leading to valuation compression for smaller or less profitable startups. Capital Costs: Higher interest rates make it more expensive for buyers to finance large transactions, contributing to the cautious nature of the M&amp;A market. To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a> &nbsp;

10 Key Factors European HealthTech Founders should be aware of in today's M&A and funding environment

Soap bubbles isolated on black background. Bright soap bubble perfect for digital composing. Abstract Liquid Colorful Motion background.

Fears of a "trillion-dollar AI bubble" could have a profound and differentiating impact on the HealthTech sector, separating companies with solid clinical and financial proof from those merely relying on AI buzz for high valuations.The impact can be categorised into a few key areas:1. Venture Capital and Investment ContractionA market correction in the broader AI space would lead to a significant tightening of capital, directly impacting healthtech funding.Valuation Correction (The "De-Hype"): Healthtech startups that have commanded premium valuations (which in 2025 were reportedly up to 50% higher than the industry average for AI-focused firms) based purely on using "AI" or "GenAI" in their pitch will face the steepest cuts. Investors will no longer tolerate the "potential" for AI and will demand evidence of measurable, tangible ROI in a clinical or administrative setting. The Funding Chill: Early-stage (Seed, Series A) funding rounds may slow down drastically as VCs become more risk-averse. Companies with long time-to-market, particularly those in complex drug discovery or novel clinical decision support, may struggle to raise follow-on capital. Flight to Quality: Capital will consolidate around established healthtech leaders that have a clear path to profitability, significant revenue, and validated, peer-reviewed clinical data. The focus will shift from rapid growth at all costs to capital efficiency and sustainable business models.2. Operational and Financial ScrutinyThe "bubble burst" forces a shift from "we use AI" to "how does your AI save lives/money?"Demand for ROI Metrics: The health system, already cautious, will become even more skeptical. Healthtech companies must prove their AI tools deliver a clear return on investment, such as: Cost Savings: Documented reduction in administrative overhead (e.g., automated coding, claims processing). Clinical Efficacy: Measurable improvement in patient outcomes (e.g., reduced hospital readmissions, faster diagnosis times).Productivity Gains: Quantifiable time savings for clinicians (e.g., AI scribes for doctors). M&amp;A Dominance: With IPO markets potentially frozen for unproven companies, mergers and acquisitions (M&amp;A) will become the dominant exit strategy. Large, cash-rich tech companies or established healthcare players will acquire smaller, struggling AI startups at lower valuations to buy talent and technology.3. The Great Healthtech Divide (Clinical vs. Administrative AI)A market correction is likely to accelerate the trend of investment favouring certain, lower-risk AI applications.Administrative/Workflow AI (e.g., RCM, billing, staffing) These applications have a clearer, faster ROI by addressing the immediate problem of high labor costs and inefficiency. They don't require lengthy clinical trials, making them less risky to implement and fund. Core Clinical AI (e.g., diagnostic imaging, drug discovery) The sales cycles are long, regulatory hurdles (FDA/CE) are high, and the time to prove efficacy is measured in years. Funding for these will become scarce unless the company already has strong partnerships or major trial milestones. Generative AI for Physicians (e.g., clinical note summarisation) The utility is undeniable, but buyers will only pay for solutions that prove to be completely accurate, secure, and integrated into existing Electronic Health Records (EHRs). Vague "AI-powered" solutions will be discarded.4. A Focus on Trust, Safety and RegulationA bubble mentality often overlooks ethical and safety concerns in the rush for profit; a correction forces a reckoning.De-risking the Technology: Investors and buyers will prioritise healthtech solutions that emphasise explainability (why the AI made a certain recommendation), clinical validation, and data privacy(HIPAA/GDPR compliance). Regulatory Focus: The market will reward companies that actively work with regulators and prove their AI models are fair and unbiased across diverse patient populations, making regulatory compliance a funding requirement rather than an afterthought. In essence, a burst AI bubble in healthtech would be painful in the short term, but ultimately beneficial, as it would cleanse the market of over-hyped, under-delivering solutions and force the remaining companies to build truly valuable, scientifically sound products.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

How could fears of a "Trillion Dollar AI Bubble" impact the HealthTech sector in the USA and Europe?

Nelson Advisors will be speaking, presenting and chairing a number of panels at HealthTech conferences and events in October, November and December 2025.October 2025Healthcare Summit 2025, London, UK – Chairing the HealthTech M&amp;A PanelHealthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring PanelNHS Clinical Entrepreneur Conference, Belfast, Northern Ireland – Attending the NHS Innovation Accelerator sessionsGlobal Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&amp;A PanelNovember 2025HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” PanelMedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates &amp; Hospitals: How to Build Meaningful MedTech Partnerships" panelMedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch AwardsDecember 2025HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack: Emerging Vulnerabilities in Healthcare”PanelHealthInvestor Power List Awards, London, UK – Judging PanelTo discuss how Nelson Advisors can help your HealthTech or MedTech company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors MedTech and HealthTech events in October, November, December 2025

The last week in European MedTech has been dominated by regulatory and funding activities, as well as continued momentum in digital health and surgical innovation.🇪🇺 Regulatory News and Policy The central theme continues to be the implementation and potential revision of the EU's Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).Call for Evidence on MDR/IVDR Reform: The European Commission launched a "Call for Evidence" on the future of the MDR/IVDR, seeking feedback on a targeted revision. The goal is to reduce administrative burden, improve predictability, and enable digitalization in the regulations. This consultation was a major focal point for industry last week. Industry Push for Action: Industry group MedTech Europe is actively pushing for immediate regulatory changes by early 2026. Key requests include a targeted postponement of re-certification requirements to avoid regulatory bottlenecks and the creation of a single governance structure for Notified Bodies to ensure a more efficient CE-marking system. UK Regulatory Updates: The UK's MHRA (Medicines and Healthcare products Regulatory Agency) published guidance to help manufacturers prepare for a new device registration fee set to apply from April 1st. They also reported that reforms have more than halved the time it takes to approve clinical trials, falling from 91 days to 41 days. 💰 Funding and Innovation Highlights Several companies secured funding and advanced commercial rollout of innovative technologies:Remote Monitoring: French company RDS secured a €14 million Series A round to industrialise and expand its MultiSense RDS, a CE-marked connected patch for continuous remote patient monitoring across Europe. Cardiology Device Rollout: Elixir Medical began its full European rollout of the LithiX high-capacity Intravascular Lithotripsy (IVL) device following its CE mark. This rollout follows treatment of over 400 patients across 16 countries. AI and Robotics Investment: Medtronic plc announced it is doubling its London presence to establish a global hub for surgical robotics and AI, aligning with long-term health plan ambitions in the UK. AI for Veterinary MedTech: UK startup Lupa raised a €17 million Series A to scale its AI-native operating system for veterinary clinics, demonstrating AI's spread into adjacent healthcare sectors. 🌐 Global &amp; Other European MedTech Updates FDA Inspection Reliance: The European Medicines Agency (EMA) has begun accepting the FDA's findings from inspections of manufacturing facilities conducted outside the US, a significant step toward international regulatory harmonisation. Pharmaceutical Cost Debate: Under the UWWTD's (Urban Waste Water Treatment Directive) extended producer responsibility scheme, pharmaceutical and cosmetics industries will be required to contribute to wastewater treatment costs. This plan has received pushback from major European drugmaker trade groups.To discuss how Nelson Advisors can help your HealthTech or MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Google's parent company Alphabet launches Verily Me, a fr...

Why is a lot of the European HealthTech market distressed...

10 Key Factors European HealthTech Founders should be awa...

How could fears of a "Trillion Dollar AI Bubble" impact t...

Nelson Advisors MedTech and HealthTech events in October,...

This Week in European MedTech - Week 3 October 2025